PRA Health Sciences (PRAH) Reports In-Line Q3 EPS

PRA Health Sciences (NASDAQ: PRAH) reported Q3 EPS of $0.64, in-line with the analyst estimate of $0.64. Revenue for the quarter came in at $399.8 million versus the consensus estimate of $394.87 million.

GUIDANCE:

PRA Health Sciences sees FY2016 EPS of $2.45-$2.48, versus the consensus of $2.47.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
• Western Digital (WDC) Tops Q3 EPS by 42c; offers guidance